Cranenburgh R M, Hanak J A, Williams S G, Sherratt D J
Cobra Therapeutics Ltd, The Science Park, Keele, Staffordshire ST5 5SP, UK.
Nucleic Acids Res. 2001 Mar 1;29(5):E26. doi: 10.1093/nar/29.5.e26.
We report the construction of two novel Escherichia coli strains (DH1lacdapD and DH1lacP2dapD) that facilitate the antibiotic-free selection and stable maintenance of recombinant plasmids in complex media. They contain the essential chromosomal gene, dapD, under the control of the lac operator/promoter. Unless supplemented with IPTG (which induces expression of dapD) or DAP, these cells lyse. However, when the strains are transformed with a multicopy plasmid containing the lac operator, the operator competitively titrates the LacI repressor and allows expression of dapD from the lac promoter. Thus transformants can be isolated and propagated simply by their ability to grow on any medium by repressor titration selection. No antibiotic resistance genes or other protein expressing sequences are required on the plasmid, and antibiotics are not necessary for plasmid selection, making these strains a valuable tool for therapeutic DNA and recombinant protein production. We describe the construction of these strains and demonstrate plasmid selection and maintenance by repressor titration, using the new pORT plasmid vectors designed to facilitate recombinant DNA exploitation.
我们报告构建了两种新型大肠杆菌菌株(DH1lacdapD和DH1lacP2dapD),它们有助于在复杂培养基中进行无抗生素选择并稳定维持重组质粒。它们含有在乳糖操纵子/启动子控制下的必需染色体基因dapD。除非补充IPTG(诱导dapD表达)或DAP,否则这些细胞会裂解。然而,当用含有乳糖操纵子的多拷贝质粒转化这些菌株时,操纵子竞争性地滴定LacI阻遏物,并允许从乳糖启动子表达dapD。因此,转化体可以通过阻遏物滴定选择在任何培养基上生长的能力简单地分离和繁殖。质粒上不需要抗生素抗性基因或其他蛋白质表达序列,并且质粒选择不需要抗生素,这使得这些菌株成为治疗性DNA和重组蛋白生产的有价值工具。我们描述了这些菌株的构建,并使用设计用于促进重组DNA利用的新型pORT质粒载体,通过阻遏物滴定证明了质粒的选择和维持。